In a report published Thursday, Benchmark Company analyst Jan Wald initiated coverage on LeMaitre Vascular LMAT with a Buy rating and $9.00 price target.
In the report, Benchmark Company noted, “We are initiating coverage on LeMaitre Vascular with a Buy rating and a $9 price target. We believe that the company's well-established position within the vascular surgeon community, and its focus on niche products that typically do not attract competition from the industry giants, give the company a bit of a home field advantage. We believe they are capitalizing on this opportunity. Its growth strategy has relied heavily on small tuck-in acquisitions, and we believe that in the coming years the company could become more open to larger deals which could open up more markets within its core competencies. We believe 10%+ annual revenue growth and a $0.12 annual dividend provides investors with reasons to own the stock ahead of any moves to a more Street-friendly facing.”
LeMaitre Vascular closed on Wednesday at $6.97.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorInitiationAnalyst RatingsBenchmark CompanyHealth CareHealth Care EquipmentJan Wald
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in